KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Cash from Investing Activities (2018 - 2025)

ClearPoint Neuro's Cash from Investing Activities history spans 13 years, with the latest figure at -$199000.0 for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 1558.33% year-over-year to -$199000.0; the TTM value through Sep 2025 reached -$736000.0, down 268.0%, while the annual FY2024 figure was -$275000.0, 103.07% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$199000.0 at ClearPoint Neuro, down from -$91000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $11.7 million in Q4 2022 and bottomed at -$21.7 million in Q2 2022.
  • The 5-year median for Cash from Investing Activities is -$138000.0 (2023), against an average of -$159000.0.
  • The largest YoY upside for Cash from Investing Activities was 31010.53% in 2022 against a maximum downside of 62002.86% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$38000.0 in 2021, then skyrocketed by 31010.53% to $11.7 million in 2022, then crashed by 101.6% to -$188000.0 in 2023, then plummeted by 39.89% to -$263000.0 in 2024, then increased by 24.33% to -$199000.0 in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Cash from Investing Activities are -$199000.0 (Q3 2025), -$91000.0 (Q2 2025), and -$183000.0 (Q1 2025).